Celvia CC AS

What Celvia CC AS does

Celvia CC AS is an Estonian genetic testing company and research institution headquartered in Tartu, Estonia, with shareholders including the University of Tartu and Tartu University Hospital. The company was formerly known as the Health Technologies Development Centre (CCHT) before rebranding to Celvia. It operates as a privately held, science-based B2B/B2B2C provider offering proprietary DNA-based diagnostic tests, primarily to healthcare providers, fertility clinics, and food safety clients in Estonia and the Baltic region.

Its product portfolio spans six tests built on DNA sequencing and molecular diagnostics: NIPTIFY (non-invasive prenatal testing for fetal chromosomal diseases from a maternal blood sample), beREADY (personalised medicine test for infertility treatment planning), PGT-A (preimplantation genetic testing for embryo selection), CLARITY (non-invasive pregnancy loss chromosomal analysis from 6 weeks gestation), InvisibleMi (microbiome testing of the genital tract), and MDA (honey DNA metagenomic analysis for origin and adulteration verification). The underlying technology relies on established sequencing platforms combined with proprietary analytical methods, supported by ISO 15189:2022 and ISO 17025:2017 certifications and an Estonian Health Board activity licence.

Celvia monetises through clinical testing services sold to hospitals, fertility clinics, and food producers, with non-public pricing negotiated per client. Revenue is supplemented by EU and Estonian public funding (Interreg Estonia-Latvia programme covering 80% of ENTER and NOVAFERT projects, Enterprise Estonia co-financing for SCANS and ReadUteru, and PRIA funds for honey research). Distribution is primarily direct sales to healthcare providers in Estonia, with emerging cross-border delivery to Latvia via Latvian clinic partners. Marketing is driven by traditional media coverage, peer-reviewed publications (300+ articles), and a modest social media presence on Facebook and Instagram.

Name

Celvia CC AS

Legal name

Celvia CC AS

Website

https://celvia.ee

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Celvia CC AS is an Estonian genetic testing company developing and delivering DNA-based diagnostic tests for prenatal screening, fertility treatment, microbiome analysis, and honey authentication, serving healthcare providers, fertility clinics, and food safety clients primarily in Estonia and the Baltic region.

Ownership category

akta.pro rank

Product category

Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Genetic testing services
• Prenatal screening
• Fertility diagnostics
• Non-invasive testing
• Molecular diagnostics

Headquarters

HQ city

Tartu

HQ country

Estonia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Services: Revenue from providing clinical genetic testing services including NIPTIFY (prenatal screening), beREADY (fertility), PGT-A (embryo selection), InvisibleMi (microbiome), CLARITY (pregnancy loss), and MDA (honey analysis). Services are offered to healthcare providers, clinics, and patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Celvia CC AS develops and delivers genetic tests and accredited laboratory services for reproductive medicine, prenatal screening, fertility treatment, microbiome analysis, and honey authentication. Its core offerings — NIPTIFY, beREADY, PGT-A, InvisibleMi, CLARITY, and MDA — are proprietary DNA-based diagnostic tests sold to clinicians, fertility clinics, hospitals, and food industry clients and processed in its ISO-accredited Tartu laboratory.

Product overview

Celvia CC AS is an Estonian genetic testing company and research institution that offers a portfolio of science-based diagnostic products. The core offerings include NIPTIFY (non-invasive prenatal testing for fetal chromosomal diseases), beREADY (personalized medicine test for infertility treatment), InvisibleMi (microbial community testing for reproductive tract health), PGT-A Test (embryo selection for fertility treatment), CLARITY (pregnancy loss chromosomal analysis), and MDA (honey DNA metagenomic analysis for food authenticity). These products combine advanced genetic analysis with medical diagnostics, serving both healthcare and food safety industries.

Differentiator

Problem solved

Functional benefit

Brands

• NIPTIFY: Accurate and safe prenatal screening test that analyses the most important fetal chromosomal diseases using a single maternal blood sample.
• beREADY
• InvisibleMi
• PGT-A Test
• Mee DNA Analüüs (MDA)
• CLARITY

Products and services

• NIPTIFY A precise, safe non-invasive prenatal test that analyses the most important fetal chromosomal diseases from a single maternal blood sample. Targeted at obstetricians, gynaecologists, and hospital laboratories for routine prenatal screening.
• beREADY Personalised medicine test for infertility treatment that supports planning of embryo transfer and design of treatment plans. Used by fertility clinics, IVF specialists, and reproductive medicine clinicians.
• InvisibleMi A private test for detecting and monitoring microbial communities in the female and male genital tract. Used by reproductive health and fertility clinicians for microbiome-informed patient management.
• PGT-A Test Precision medicine test for infertility treatment that selects embryos with healthy chromosomes for transplantation in IVF. Used by fertility clinics, embryologists, and IVF specialists.
• Mee DNA Analüüs (Honey DNA Metagenomic Analysis, MDA) Comprehensive honey DNA metagenomic analysis test providing detailed information on honey composition, botanical origin, geographical origin, and adulteration detection. Targeted at beekeepers, honey producers, and food safety laboratories.
• CLARITY Innovative non-invasive test for identifying chromosomal causes of pregnancy loss from as early as 6 weeks of gestation, requiring only a single blood sample. Used by obstetricians, gynaecologists, and pregnancy-loss specialists for early clinical investigation.

Quantifiable outcome

• Non-invasive prenatal screening for fetal chromosomal diseases
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered major, minor and core.

• Riga Stradiņš UniversitymajorStrategic or Co-development Partner · 1 September 2024Latvian university partner in the NOVAFERT project for developing genetic tests for infertility. Partnership establishes foundation for ongoing collaboration in medical genetics research in the EstLat cross-border region.
• GenEramajorStrategic or Co-development Partner · 1 October 2023Latvian clinic partner in the ENTER project for obstetric care and NIPT services. Part of cross-border collaboration to extend non-invasive prenatal testing to Latvia using the existing Estonian NIPTIFY service.
• Ģimenes sirdsmajorStrategic or Co-development Partner · 1 October 2023Latvian clinic partner in the ENTER project for obstetric care and NIPT services in Latvia.
• DubultumajorStrategic or Co-development Partner · 1 October 2023Latvian clinic partner in the ENTER project for obstetric care and NIPT services in Latvia.
• SYNLAB Eesti OÜmajorTechnology or Integration · 1 October 2023Partner in SCANS project for sepsis diagnostics development. Collaboration involves developing liquid biopsy methods for sepsis diagnosis using microbial DNA sequencing.
• Muhe Mesi OÜminorStrategic or Co-development Partner · 1 July 2020Research partner in honey DNA analysis project (MDA). Muhe Mesi OÜ is the main implementer of the honey DNA analysis project in Estonia, with Celvia as the scientific research partner.
• University of TartucoreStrategic or Co-development PartnerShareholder of Celvia CC AS. Collaborates on basic and applied research in genetics, biomedicine, and molecular biology. Celvia was formerly the Health Technologies Development Centre (CCHT) and maintains close ties with the university for research projects and talent development.
• Tartu University HospitalcoreStrategic or Co-development PartnerShareholder of Celvia CC AS. Collaborates on clinical research and application of genetic tests in healthcare settings. Partnership enables validation of diagnostic tests through clinical studies and patient samples.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• SYNLAB: Europe's largest medical diagnostics services provider; SYNLAB Eesti is a Celvia partner in the SCANS sepsis project. Overlapping clinical lab capabilities across routine and specialty diagnostics.
• LabCorp: Global clinical laboratory network offering reproductive and prenatal genetic testing as part of broad diagnostics portfolio. Not niche-focused but competes for the same hospital and clinic accounts.
• Natera: Large US-based genetic testing company with Panorama NIPT, Empower PGT, and Vistara carrier screening. Direct product overlap with NIPTIFY, beREADY, and PGT-A but at much greater scale and geographic reach.
• Quest Diagnostics: US-based broad diagnostics incumbent with QNatal NIPT and hereditary cancer screening. Larger scale and broader menu, overlapping with Celvia's prenatal and reproductive genetic testing services.

Emerging players

• Genomic Prediction: Specialized reproductive genetics company focused on PGT-A and PGT-P embryo screening. Directly overlaps with Celvia's PGT-A offering in the IVF clinic channel.
• Juno Genetics: UK-based reproductive genetics lab offering PGT-A, PGT-M, NIPT, and endometrial receptivity testing. Closely comparable niche focus on IVF/genetic testing services.

Direct peers

• Eurofins Genoma: European clinical genetics laboratory offering NIPT, PGT, and reproductive genetic testing. Listed in Celvia's scientific collaboration network and operates the same clinical lab service model in Europe.
• Centogene: European rare disease and reproductive genetics lab offering NIPT, PGT, and carrier screening. Closely comparable business model and customer base as a clinical genetics lab serving clinicians and patients.
• Medicover Genetics: European clinical lab offering NIPT, PGT-A, and carrier screening across multiple countries. Comparable service menu, customer base (OB/GYNs and fertility clinics), and geographic focus on Central/Eastern Europe.
• Igenomix: Global reproductive genetics lab specializing in PGT-A, NIPT, and carrier screening. Listed as a Celvia collaborator and competes directly in IVF/fertility genetic testing with similar service offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/meditsiinilabor
• Instagraminstagram.com/celvialaboratory
• LinkedInlinkedin.com/company/celvia-cc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celvia CC AS